SIALYL LEWISx AS A TUMOR-ASSOCIATED CARBOHYDRATE ANTIGEN IN BREAST CANCER

Abstract

Operative breast cancers were subjected to a serological and immunohistochemical evaluation of sialyl Lewisx antigen as a tumor-associated one, where a new monoclonal antibody CSLEX1 which reacts with sialyl Lewisx antigen was used. Percent positive of sailayl Lewisx in sera of 30 patients with breast cancer was 30%(9/30), which was better than those of any other tumor markers such as CEA, CA19-9, CA15-3 and SLX. Percent positives, according to clinical stages, were 20.0%, 37.5%, 40.0% and 50.0% in stage I, II, III and IV respectively. Immunohistochemically, the expression of a sialyl Lewisx in the normal ductal epithelium and carcinoma cells of 41 breast cancers demonstrated 95.5%(21/22) and 65.9%(27/41) respectively. Although the immunohistochemical experssion of sialyl Lewisx antigen indicated a low cancer specificity, comparatively high positive rates in stage I and II were obtained in sera of cancer patients. It has been suggested that sialyl Lewisx antigen is useful as a tumor-associatd antigen in breast cancers.

Meningeal carcinomatosis preceded by a rapid increase in serum CA19-9 levels in a patient with breast cancer

“…[1][2][3][4][5] The development of meningeal carcinomatosis from breast cancer is also rare. 6 Meningeal carcinomatosis is diagnosed based on the appearance of carcinoma cells in the cerebrospinal fluid (CSF).…”